1/28
08:03 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $80.00 price target on the stock.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) is now covered by analysts at Barclays PLC. They set an "overweight" rating and a $80.00 price target on the stock.
1/20
07:55 am
bmrn
Rating for BMRN
Medium
Report
Rating for BMRN
1/20
05:05 am
bmrn
BioMarin upgraded to Buy from Hold at Canaccord
Low
Report
BioMarin upgraded to Buy from Hold at Canaccord
12/3
08:42 am
bmrn
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock, down previously from $82.00.
Low
Report
BioMarin Pharmaceutical (NASDAQ:BMRN) had its "market perform" rating reaffirmed by analysts at Leerink Partners. They now have a $60.00 price target on the stock, down previously from $82.00.
12/3
08:34 am
bmrn
Rating for BMRN
Low
Report
Rating for BMRN
12/3
06:31 am
bmrn
BioMarin downgraded to Market Perform from Outperform at Leerink
Low
Report
BioMarin downgraded to Market Perform from Outperform at Leerink
12/3
06:10 am
bmrn
BioMarin downgraded to Market Perform from Outperform at Leerink
Low
Report
BioMarin downgraded to Market Perform from Outperform at Leerink